Search clinical trials for: osimertinib

Total 282 results

The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Osimertinib as Neoadjuvant Therapy in Patients With Resectable Stage II-IIIB EGFR-mutated Lung Squamous Cell Carcinoma (GALAXY-02)

Carcinoma, Squamous Cell | Lung Cancer

China
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
AstraZeneca

Not yet recruiting

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC (FOREFRONT)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms

China
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

China, Taiwan, Korea, Republic of, Australia
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
Taizhou Hospital

Not yet recruiting

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Lung Cancer, Nonsmall Cell
Suzhou Genhouse Bio Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

China
Guangzhou Medical University

Recruiting

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Leptomeningeal Metastasis

China
Guangzhou Medical University

Not yet recruiting

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Leptomeningeal Metastasis
Jair Bar, M.D., Ph.D.

Not yet recruiting

Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib

Non-squamous NSCLC
AstraZeneca

Not yet recruiting

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA)

Lung Cancer

Thailand, Vietnam, Korea, Republic of, India, China, Taiwan, United States, Israel, Spain, Turkey
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication
Hunan Province Tumor Hospital

Recruiting

Efficacy of Osimertinib in Patients With Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Non Small Cell Lung Cancer | Immune Checkpoint Inhibitor | EGFR Exon 21 Mutation

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Non Small Cell Lung Cancer | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage IIIA
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Non Small Cell Lung Cancer

China
AbbVie

Not yet recruiting

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Non-Small Cell Lung Cancer
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
AstraZeneca

Recruiting

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain (OSIREAL)

Non-small Cell Lung Cancer

Spain
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR L858R | EGFR DEL19

France
AstraZeneca

Recruiting

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region (TREASURE)

Carcinoma, Non-Small-Cell Lung

Kuwait, Saudi Arabia, United Arab Emirates, Qatar
LianBio LLC

Recruiting

BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

NSCLC

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Non Small Cell Lung Cancer | EGFR Gene Mutation
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
Centro de Tratamiento e Investigación sobre Cáncer...

Not yet recruiting

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) (CULTRO)

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Exon 19 Deletion | EGFR G719X | EGFR Exon 21 Mutation

Colombia
Genentech, Inc.

Recruiting

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Colorectal Cancer | Non-Small Cell Lung Cancer

Korea, Republic of, Australia, United States
TYK Medicines, Inc

Recruiting

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

NSCLC | Brain Metastases | EGFR Activating Mutation

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Pfizer

Recruiting

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (DELINOR)

Non-Small Cell Lung Cancer

Norway
Klus Pharma Inc.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA)

Non-Small Cell Lung Cancer (NSCLC)

Korea, Republic of, Malaysia, Taiwan, Thailand, Hong Kong, Singapore, Canada
Honglan Zhu

Recruiting

The Study on the Therapeutic Effect and Mechanism of Transcutaneous Acupoint Electrical Stimulation in Female

Dysmenorrhea

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. (TEMPLE-2)

Non Small Cell Lung Cancer

Italy
National Cancer Centre, Singapore
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

NSCLC

Singapore
Maastricht University Medical Center

Recruiting

Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat (OSIBOOST-2)

Non-small Cell Lung Cancer

Netherlands
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China
AstraZeneca

Recruiting

First in Human Study of AZD9592 in Solid Tumors (EGRET)

Head and Neck Neoplasms | Colorectal Neoplasms | Advanced Solid Tumours | Carcinoma Non-small Cell Lung

United States, China, Korea, Republic of, Spain, Australia, Japan, Taiwan, Canada, France, Italy, Malaysia
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
AstraZeneca
Parexel

Recruiting

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) (ROSY-T)

Cancer

China, Taiwan, France, United Kingdom, Korea, Republic of, Malaysia, Thailand, Poland
Li Zhang
Hubei Cancer Hospital

Not yet recruiting

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Stage IV Non-small Cell Lung Cancer

China
AstraZeneca

Recruiting

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

Non-small Cell Lung Cancer

China
Samsung Medical Center

Recruiting

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Lung Adenocarcinoma

Korea, Republic of
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations

China
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Non Small Cell Lung Cancer

China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
Jiesi Yingda Pharmaceutical Technology (Suzhou)...

Recruiting

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (VIC-1911)

Advanced Non-small Cell Lung Cancer

China
Jin Hyoung Kang
Korea University Anam Hospital

Not yet recruiting

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Non-small Cell Lung Cancer

Korea, Republic of

3

Subscribe